Tuesday, November 3, 2026
  • About Web3Wire
  • Web3Wire NFTs
  • .w3w TLD
  • $W3W Token
  • Web3Wire DAO
  • Media Network
  • RSS Feed
  • Contact Us
Web3Wire
No Result
View All Result
  • Home
  • Web3
    • Latest
    • AI
    • Business
    • Blockchain
    • Cryptocurrencies
    • Decentralized Finance
    • Metaverse
    • Non-Fungible Token
    • Press Release
  • Technology
    • Consumer Tech
    • Digital Fashion
    • Editor’s Choice
    • Guides
    • Stories
  • Coins
    • Top 10 Coins
    • Top 50 Coins
    • Top 100 Coins
    • All Coins
  • Exchanges
    • Top 10 Crypto Exchanges
    • Top 50 Crypto Exchanges
    • Top 100 Crypto Exchanges
    • All Crypto Exchanges
  • Stocks
    • Blockchain Stocks
    • NFT Stocks
    • Metaverse Stocks
    • Artificial Intelligence Stocks
  • Events
  • News
    • Latest Crypto News
    • Latest DeFi News
    • Latest Web3 News
  • Home
  • Web3
    • Latest
    • AI
    • Business
    • Blockchain
    • Cryptocurrencies
    • Decentralized Finance
    • Metaverse
    • Non-Fungible Token
    • Press Release
  • Technology
    • Consumer Tech
    • Digital Fashion
    • Editor’s Choice
    • Guides
    • Stories
  • Coins
    • Top 10 Coins
    • Top 50 Coins
    • Top 100 Coins
    • All Coins
  • Exchanges
    • Top 10 Crypto Exchanges
    • Top 50 Crypto Exchanges
    • Top 100 Crypto Exchanges
    • All Crypto Exchanges
  • Stocks
    • Blockchain Stocks
    • NFT Stocks
    • Metaverse Stocks
    • Artificial Intelligence Stocks
  • Events
  • News
    • Latest Crypto News
    • Latest DeFi News
    • Latest Web3 News
No Result
View All Result
Web3Wire
No Result
View All Result
Home Press Release GlobeNewswire

GlycoDefender Capsules Introduces Glyco Defender Multi-Ingredient Dietary Supplement

October 10, 2026
in GlobeNewswire, Web3
Reading Time: 22 mins read
5
SHARES
247
VIEWS
Share on TwitterShare on LinkedInShare on Facebook

Glyco Defe de a ou ceme t outli es a bota ical fo mulatio co tai i g maca oot, Af ica ma go, g ape seed, gua a a seed, eleuthe o oot, a d g ee tea leaf ext act.

Ogde , UT, Oct. 09, 2026 (GLOBE NEWSWIRE) — GlycoDefe de has i t oduced Glyco Defe de , a multi-i g edie t dieta y suppleme t fo mulated with six bota ical i g edie ts: maca oot (Lepidium meye ii), Af ica ma go (I vi gia gabo e sis), g ape seed (Vitis vi ife a), gua a a seed (Paulli ia cupa a), eleuthe o oot (Eleuthe ococcus se ticosus), a d g ee tea leaf ext act. The fo mulatio b i gs togethe pla t-de ived i g edie ts with diffe e t t aditio al uses a d a eas of scie tific i te est.

Official Website: https://glyco-defe de .shop/

The p oduct a ou ceme t p ovides a oppo tu ity to exami e the listed bota icals, thei k ow cha acte istics, a d the impo ta ce of accu ate i fo matio whe discussi g suppleme ts associated with blood suga suppo t. Although bota ical i g edie ts a e used i a va iety of dieta y suppleme ts, thei p ese ce i a fo mulatio does ot automatically establish that the fi ished p oduct p oduces a pa ticula health outcome.

Blood glucose egulatio is a complex physiological p ocess i flue ced by facto s such as ut itio , physical activity, ho mo es, medicatio s, a d ove all health. Evaluati g a suppleme t i this catego y equi es atte tio to its complete compositio , i g edie t qua tities, a d evide ce elati g to the specific p oduct a d its i te ded use.

The i g edie t i fo matio supplied fo Glyco Defe de does ot i clude dosages, sta da dized ext act specificatio s, p oduct-specific cli ical t ial esults, o i depe de tly ve ified fi di gs about blood glucose outcomes. This a ou ceme t the efo e focuses o the fo mulatio a d ge e al scie tific co text athe tha p ese ti g u ve ified be efits as established facts.

A Ove view of the GlycoDefe de Fo mulatio

GlycoDefe de is desc ibed as a multi-i g edie t dieta y suppleme t co tai i g six bota ical compo e ts. These i clude oots, seeds, a d pla t ext acts sou ced f om diffe e t species.

Maca oot o igi ates f om the A dea egio of South Ame ica, while Af ica ma go is associated with West a d Ce t al Af ica. G ape seed is de ived f om the f uit of the g apevi e, gua a a comes f om a Amazo ia pla t, a d eleuthe o is a pla t ative to pa ts of o theaste Asia. G ee tea leaf ext act is p oduced f om the leaves of Camellia si e sis.

Each bota ical has a disti ct chemical compositio . Depe di g o the pla t mate ial a d ext actio p ocess, ext acts may co tai diffe e t p opo tio s of atu ally occu i g compou ds, i cludi g polyphe ols, catechi s, a d othe phytochemicals.

The actual compositio of a bota ical ext act depe ds o facto s such as the pla t va iety, g owi g co ditio s, p ocessi g methods, a d ext actio specificatio s. Co seque tly, the commo ame of a i g edie t does ot p ovide e ough i fo matio to establish its co ce t atio o biological activity i a fi ished suppleme t.

Fo Glyco Defe de , the six listed bota icals ide tify the i g edie ts supplied fo this a ou ceme t. Thei i dividual qua tities, ext act atios, a d sta da dizatio details have ot bee p ovided.

Maca Root a d Its Bota ical Cha acte istics

Maca, scie tifically ide tified as Lepidium meye ii, is a pla t cultivated i the high-altitude egio s of the A des. Its oot has a histo y of use as a food a d i t aditio al p actices.

Maca co tai s a a ge of atu ally occu i g pla t compou ds, a d its ut itio al a d chemical cha acte istics ca va y acco di g to cultivatio a d p ocessi g. Resea che s have i vestigated maca i elatio to seve al a eas of huma health, although fi di gs f om i dividual studies ca ot automatically be applied to eve y p oduct co tai i g the oot.

The te m “adaptoge ” is commo ly used i suppleme t ma keti g a d t aditio al he bal discussio s to desc ibe ce tai pla ts believed to help the body espo d to st ess. Howeve , the scie tific mea i g a d suppo ti g evide ce fo adaptoge ic effects va y by i g edie t a d i te ded outcome.

Fo Glyco Defe de , maca oot is o e of the six supplied bota ical i g edie ts. The available i fo matio does ot specify the amou t used, the ext act’s compositio , o a y p oduct-specific esea ch demo st ati g a effect o blood glucose.

Its i clusio should the efo e be u de stood as pa t of the fo mulatio athe tha p oof that the fi ished suppleme t imp oves glucose egulatio o t eats a metabolic co ditio .

Af ica Ma go a d Its Seed Ext act

Af ica ma go, ide tified as I vi gia gabo e sis, is a t ee ative to pa ts of West a d Ce t al Af ica. Its f uit is used as food, while its seeds have bee i vestigated fo seve al pote tial ut itio al a d metabolic applicatio s.

Af ica ma go seed ext acts have att acted esea ch i te est i a eas i cludi g body weight a d metabolic health. Howeve , studies diffe i thei desig , pa ticipa t populatio s, ext act p epa atio s, a d measu ed outcomes. Results f om o e p epa atio should ot be assumed to apply to all p oducts co tai i g Af ica ma go.

The chemical compositio of a ext act ca depe d o how the seeds a e p ocessed a d which co stitue ts a e co ce t ated du i g p oductio . I fo matio about the ext actio method a d i g edie t specificatio s is the efo e eleva t whe assessi g a suppleme t.

I the supplied GlycoDefe de fo mulatio , Af ica ma go is ide tified as a seed ext act. No ext act atio, sta da dized co stitue t level, o p oduct-specific cli ical fi di gs have bee p ovided.

The i g edie t’s i clusio does ot i depe de tly establish that Glyco Defe de educes blood glucose, cha ges body weight, o imp oves metabolic health. Such co clusio s equi e evide ce eleva t to the fi ished p oduct a d the pa ticula outcome bei g claimed.

G ape Seed a d Natu ally Occu i g Polyphe ols

G ape seed, de ived f om Vitis vi ife a, is a sou ce of atu ally occu i g pla t compou ds, i cludi g polyphe ols. Some g ape seed ext acts co tai p oa thocya idi s, a g oup of compou ds i vestigated fo thei chemical a d biological p ope ties.

Polyphe ols a e widely studied because of thei i te actio s with biological systems. Neve theless, the p ese ce of polyphe ols i a i g edie t does ot by itself demo st ate a cli ical be efit f om co sumi g a suppleme t co tai i g that i g edie t.

Ext act compositio ca va y acco di g to g ape va iety, p ocessi g co ditio s, a d ma ufactu i g specificatio s. The co ce t atio of pa ticula compou ds is the efo e a impo ta t co side atio whe compa i g esea ch fi di gs with a comme cial fo mulatio .

G ape seed ext act is i cluded i Glyco Defe de ‘s supplied i g edie t list. The i fo matio p ovided does ot ide tify its dosage, p oa thocya idi co ce t atio , o a y p oduct-specific evide ce elati g to blood suga egulatio .

It would be i app op iate to i fe a measu able effect o glucose levels solely f om the p ese ce of g ape seed polyphe ols. P oduct-specific claims equi e eliable evide ce that di ectly add esses the outcome i questio .

Gua a a Seed a d Its Chemical Compositio

Gua a a, scie tifically k ow as Paulli ia cupa a, is a pla t ative to the Amazo egio . Its seeds co tai caffei e a d othe atu ally occu i g compou ds.

Gua a a is used i a va iety of food a d suppleme t fo mulatio s. Its effects depe d o the amou t co sumed, the co ce t atio of caffei e, the othe i g edie ts p ese t, a d i dividual se sitivity.

Because caffei e is a stimula t, the total caffei e co te t of a fi ished suppleme t may be eleva t to people who co sume coffee, tea, e e gy d i ks, o othe p oducts co tai i g caffei e. The amou t p ese t i a gua a a ext act ca va y co side ably acco di g to its p epa atio .

The Glyco Defe de i g edie t i fo matio ide tifies gua a a seed but does ot p ovide its co ce t atio o caffei e co te t. It also does ot establish whethe the fi ished p oduct co tai s othe caffei e sou ces.

These details a e impo ta t whe evaluati g the p oduct’s compositio a d co side i g i dividual suitability. Gua a a’s i clusio does ot establish that the suppleme t imp oves blood suga egulatio , i c eases e e gy expe ditu e, o p oduces a specific metabolic outcome.

Eleuthe o Root a d T aditio al He bal Use

Eleuthe o, o Eleuthe ococcus se ticosus, is a pla t ative to pa ts of o theaste Asia. Its oot has a histo y of use i t aditio al he bal p actices a d has bee i vestigated fo va ious physiological effects.

Eleuthe o is sometimes desc ibed as a adaptoge ic he b. As with othe bota icals give this label, the st e gth of scie tific evide ce depe ds o the specific effect, p epa atio , a d study desig .

The chemical compositio of eleuthe o p epa atio s ca diffe acco di g to the sou ce mate ial, ext actio method, a d sta da dizatio p ocess. A i g edie t’s t aditio al use does ot ecessa ily demo st ate that eve y mode ext act p oduces the same effects.

Fo Glyco Defe de , eleuthe o oot is listed as o e of the six bota ical i g edie ts. The supplied i fo matio does ot ide tify the amou t used o p ovide cli ical evide ce showi g that the fi ished suppleme t p oduces a measu able cha ge i blood glucose.

A y claim elati g to glucose co t ol o a othe health outcome would equi e app op iate suppo ti g evide ce a d complia ce with the eleva t egulato y equi eme ts.

G ee Tea Leaf Ext act a d Catechi s

G ee tea is p oduced f om the leaves of Camellia si e sis. G ee tea leaf ext acts may co tai catechi s, a g oup of atu ally occu i g polyphe ols that have bee studied i ut itio al a d metabolic esea ch.

The compositio of g ee tea ext act depe ds o facto s i cludi g the sou ce leaves, p ocessi g methods, ext actio p ocedu es, a d co ce t atio of i dividual compou ds. Some p epa atio s co tai diffe i g amou ts of epigallocatechi gallate, commo ly k ow as EGCG, alo gside othe catechi s.

Resea ch i volvi g g ee tea a d its co stitue ts cove s a a ge of topics, but fi di gs ca diffe acco di g to the fo mulatio , dose, a d outcome measu ed. Evide ce about b ewed g ee tea ca ot automatically be applied to a co ce t ated ext act i a dieta y suppleme t.

Fo GlycoDefe de , the supplied i fo matio ide tifies g ee tea leaf ext act as a catechi – ich i g edie t. Howeve , o catechi co ce t atio , EGCG level, o se vi g qua tity has bee p ovided.

Co ce t ated g ee tea ext acts may also have safety co side atio s, i cludi g pote tial live – elated co ce s i ce tai ci cumsta ces. P oduct compositio a d di ectio s fo use should the efo e be eviewed ca efully, a d people with medical co ditio s o those taki g medici es should co sult a qualified healthca e p ofessio al whe app op iate.

The p ese ce of g ee tea ext act does ot i depe de tly demo st ate that GlycoDefe de lowe s blood suga o p eve ts a metabolic diso de .

Blood Suga Suppo t a d Metabolic Health

Blood glucose is egulated th ough seve al i te co ected p ocesses i volvi g i suli , the live , muscle tissue, dieta y i take, a d othe physiological systems. Glucose levels ca cha ge i espo se to meals, physical activity, st ess, medicatio , a d u de lyi g health co ditio s.

A suppleme t co tai i g bota ical i g edie ts should ot be assumed to p oduce a specific blood glucose espo se simply because i dividual pla ts have bee i vestigated i metabolic esea ch.

The six i g edie ts ide tified fo GlycoDefe de have diffe e t chemical p ofiles a d esea ch backg ou ds. Howeve , the supplied i fo matio does ot i clude p oduct-specific cli ical t ial esults, i g edie t qua tities, o evide ce establishi g the effects of the combi ed fo mulatio o blood glucose.

It would the efo e be p ematu e to co clude that GlycoDefe de lowe s blood suga , imp oves i suli se sitivity, p eve ts diabetes, o eplaces established t eatme t.

This limitatio does ot p ove that the p oduct is i effective. Rathe , the available i fo matio is i sufficie t to dete mi e its effective ess fo a y pa ticula glucose- elated outcome.

I dividuals ma agi g blood glucose levels should co ti ue to follow guida ce f om thei healthca e p ofessio als. Dieta y suppleme ts should ot eplace p esc ibed medicatio , ecomme ded mo ito i g, o evide ce-based t eatme t.

I g edie t T a spa e cy a d Scie tific Evide ce

A i g edie t list is a impo ta t sta ti g poi t fo u de sta di g a dieta y suppleme t, but it does ot p ovide eve y detail eeded to evaluate a p oduct.

Co sume s eviewi g GlycoDefe de may co side the complete i g edie t decla atio , se vi g size, amou t of each bota ical, ext act specificatio s, di ectio s fo use, a d eleva t wa i gs.

Sta da dizatio i fo matio ca be pa ticula ly useful whe a bota ical ext act is associated with specific compou ds. Without details about ext act compositio , it may be difficult to dete mi e whethe esea ch o a pa ticula p epa atio is eleva t to the p oduct bei g co side ed.

Scie tific evide ce should also be i te p eted acco di g to the outcome measu ed. A labo ato y fi di g o study i volvi g a isolated i g edie t does ot ecessa ily establish a be efit i huma s, a d a study of o e ext act ca ot automatically validate a diffe e t fo mulatio .

No p oduct-specific cli ical t ial esults, i depe de t labo ato y fi di gs, o ve ified blood glucose outcomes have bee p ovided fo GlycoDefe de i the i fo matio used fo this a ou ceme t. Co seque tly, this elease does ot att ibute a demo st ated blood suga be efit to the fi ished suppleme t.

Ge e al Co side atio s fo Suppleme t Use

People co side i g a dieta y suppleme t should eview the complete p oduct label a d co side thei i dividual health ci cumsta ces. Bota ical i g edie ts ca va y i compositio a d may i te act with medici es o be u suitable fo ce tai i dividuals.

People taki g medicatio fo diabetes o othe co ditio s affecti g blood glucose should co sult a qualified healthca e p ofessio al befo e usi g a suppleme t i te ded fo blood suga suppo t. Cha gi g medicatio o t eatme t without p ofessio al guida ce ca c eate health isks.

I dividuals who a e p eg a t o b eastfeedi g, have a existi g medical co ditio , o take p esc iptio medici es should also seek app op iate advice befo e i t oduci g a ew suppleme t.

P oduct-specific i fo matio about i g edie t qua tities, caffei e co te t, wa i gs, a d ma ufactu i g quality should be ve ified th ough official labeli g a d ma ufactu e docume tatio . Claims about testi g, ce tificatio s, o cli ical esults should be suppo ted by eliable eco ds.

These ge e al co side atio s do ot imply that GlycoDefe de has bee show to cause o p eve t a y pa ticula medical co ditio .

About the GlycoDefe de I t oductio

GlycoDefe de has i t oduced Glyco Defe de , a multi-i g edie t dieta y suppleme t whose supplied fo mulatio i cludes maca oot, Af ica ma go seed ext act, g ape seed ext act, gua a a seed, eleuthe o oot, a d g ee tea leaf ext act.

The six bota icals have disti ct o igi s a d chemical cha acte istics, a d thei ext acts may va y acco di g to sou ci g a d ma ufactu i g methods. The supplied i fo matio ide tifies the i g edie ts but does ot establish thei qua tities, sta da dized co stitue t levels, o the fi ished p oduct’s effects o blood glucose.

Fu the details f om the official p oduct label a d ma ufactu e docume tatio would be eeded to cla ify the complete fo mulatio , se vi g i st uctio s, a d applicable quality i fo matio .

The i t oductio highlights the impo ta ce of disti guishi g bota ical i g edie t i fo matio f om demo st ated health outcomes. Respo sible commu icatio about suppleme ts associated with blood suga suppo t equi es accu ate labeli g, app op iate scie tific evide ce, a d ca eful co side atio of i dividual health ci cumsta ces.

No specific effect o blood glucose o a y metabolic co ditio is established by the supplied i g edie t list alo e.

CONTACT: Email: suppo t@healthyco sume .us
Pho e: +1 (877) 257-0825 (Mo –F i, 9:00 AM – 6:00 PM EST)

About Web3Wire
Web3Wire – Information, news, press releases, events and research articles about Web3, Metaverse, Blockchain, Artificial Intelligence, Cryptocurrencies, Decentralized Finance, NFTs and Gaming.
Visit Web3Wire for Web3 News and Events, Block3Wire for the latest Blockchain news and Meta3Wire to stay updated with Metaverse News.

ShareTweet1ShareSendShare2
Previous Post

Thermo Ignite Drops Introduces ThermoIgnite Liquid Multi-Ingredient Dietary Supplement Formulation

Next Post

QTREX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement

Related Posts

IXOPAY Announces IXO One, a Modular Payments Platform Built for an Era of Fluid Commerce

Compa y i t oduces the fi st a d o ly modula , AI- ative payme ts platfo m that u ifies o chest atio , payme ts i tellige ce, a d toke izatio i a si gle offe i g; it gives me cha ts the flexibility...

Read moreDetails

Mailazy Launches Behavioral Emails: Reach Users the Moment They Act, or Get Stuck

Ma kete s w ite the t igge i o e se te ce. Mailazy se ds the email whe a use does somethi g, o stops, a d shows whethe it wo ked. SAN FRANCISCO, CA / ACCESS Newswi e / Novembe 3, 2026 / Mailazy, the email automatio...

Read moreDetails

Phrasly Launches a Free AI Image Detector as Fake Profile Photos, Listings, and News Images Become the Norm

Check a y photo fo AI a d see exactly which pa t was ge e ated. F ee, o accou t, a d it wo ks lo g afte the wate ma k is go e.DOVER, Del., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ph asly, a AI w iti...

Read moreDetails

Faraday Accelerates AI-Driven Manufacturing and Humanoid Robotics with EtherCAT-Compliant Ethernet PHY IP

HSINCHU, Taiwa , Nov. 03, 2026 (GLOBE NEWSWIRE) -- Fa aday Tech ology Co po atio (TWSE: 3035), a leadi g ASIC desig se vice a d IP p ovide , today a ou ced a e ha ced 10/100 Ethe et PHY IP solutio suppo ti g Ethe CAT...

Read moreDetails

Third Quarter Report 2026

SERSTECH GROUP, 1 JULY – 30 SEPTEMBER 2026 Net sales amou ted to KSEK 18 529 (7 765)EBITDA amou ted to KSEK 2 444 (-4 283)EBIT amou ted to KSEK 115 (-6 387)Cash flow f om ope ati g activities amou ted to KSEK -6 500 (-7 783)Ea i gs...

Read moreDetails

ZetaDisplay strengthens European presence with expansion into Iberia

MALMÖ, ZETADISPLAY AB (PUBL) – 3 Novembe 2026 ZetaDisplay is st e gthe i g its Eu opea footp i t with a expa ded comme cial p ese ce i Ibe ia. The appoi tme t of i dust y expe t Álva o Mo ales as Cou t...

Read moreDetails

INQ Group AB (publ) raises SEK 7 million under convertible loan facility from new US-based investment manager

INQ G oup AB (publ) (“INQ” o the “Compa y”), listed o Nasdaq Stockholm (ticke : INQ), a ou ces that it has aised SEK 7,000,000 of additio al capital u de its existi g secu ed co ve tible loa facility f om a US-based i vestme t ma...

Read moreDetails

Trifork strengthens its medical software capabilities with MDR certification and CE marking of nationwide medication solution

T ifo k G oup AGP ess ReleaseAa hus, De ma k, 3 Novembe 2026 (Da ish ve sio attached below) T ifo k st e gthe s its medical softwa e capabilities with MDR ce tificatio a d CE ma ki g of atio wide medicatio solutio   T...

Read moreDetails

WISeQey Announces Preliminary Nine-Month 2026 Financial Results and Provides Corporate Update

   Co solidated eve ue of $17 millio , ep ese ti g 55% yea -ove -yea g owth; eaffi ms FY 2026 eve ue guida ce of 50% to 100% yea -ove -yea g owth Subseque t WISeSat.Space Nasdaq listi g establishes dedicated public-ma ket platfo m fo secu...

Read moreDetails

SEOOnly Introduces AI Search Visibility Assessments for Australian Businesses

As mo e Aust alia s ask AI assista ts fo ecomme datio s i stead of sea chi g, Melbou e sea ch specialist SEOO ly is givi g busi ess ow e s a way to see whethe ChatGPT, Gemi i a d Claude k ow who they...

Read moreDetails
Web3Wire NFTs - The Web3 Collective

Web3Wire, $W3W Token and .w3w tld Whitepaper

Web3Wire, $W3W Token and .w3w tld Whitepaper

Claim your space in Web3 with .w3w Domain!

Web3Wire

Trending on Web3Wire

  • Top Cross-Chain DeFi Solutions to Watch by 2025

    189 shares
    Share 76 Tweet 47
  • Understanding Soulbound Tokens SBT Their Definition and Significance

    84 shares
    Share 34 Tweet 21
  • Unifying Blockchain Ecosystems: 2024 Guide to Cross-Chain Interoperability

    188 shares
    Share 75 Tweet 47
  • Top Layer 1 Crypto Projects to Watch in 2025

    38 shares
    Share 15 Tweet 10
  • Shufti Launches Know Your Agent to Verify AI Agent Identity, Human Authorization & Permissions in a Single Flow

    5 shares
    Share 2 Tweet 1
Join our Web3Wire Community!

Our newsletters are only twice a month, reaching around 10000+ Blockchain Companies, 800 Web3 VCs, 600 Blockchain Journalists and Media Houses.


* We wont pass your details on to anyone else and we hate spam as much as you do. By clicking the signup button you agree to our Terms of Use and Privacy Policy.

Web3Wire Podcasts

Upcoming Events

There are currently no events.

Latest on Web3Wire

  • IXOPAY Announces IXO One, a Modular Payments Platform Built for an Era of Fluid Commerce
  • Mailazy Launches Behavioral Emails: Reach Users the Moment They Act, or Get Stuck
  • Best Gold and Silver IRA Companies Rankings 2026 Released by Experts
  • Phrasly Launches a Free AI Image Detector as Fake Profile Photos, Listings, and News Images Become the Norm
  • Faraday Accelerates AI-Driven Manufacturing and Humanoid Robotics with EtherCAT-Compliant Ethernet PHY IP

RSS feed: Latest on Block3Wire Latest on Block3Wire

  • The Algorithmic Monographs: A Five-Volume Civil Code for the Age of Autonomous Intelligence
  • Ali Sadhik Shaik: Practitioner, Scholar, and Author – Focused on the Governance of Intelligent Systems
  • The Klyrox Protocol: A Decentralized Framework to Close the AI Accountability Gap
  • Covo Finance: Revolutionary Crypto Leverage Trading Platform
  • WorldStrides and HEX Announce Partnership to Offer High School and University Students Innovative Courses Designed to Improve Their Outlook in the Digital Age

RSS feed: Latest on Meta3Wire Latest on Meta3Wire

  • The Algorithmic Monographs: A Five-Volume Civil Code for the Age of Autonomous Intelligence
  • Ali Sadhik Shaik: Practitioner, Scholar, and Author – Focused on the Governance of Intelligent Systems
  • The Klyrox Protocol: A Decentralized Framework to Close the AI Accountability Gap
  • Thumbtack Honored as a 2023 Transform Awards Winner
  • Accenture Invests in Looking Glass to Accelerate Shift from 2D to 3D
Web3Wire

Web3Wire is your go-to source for the latest insights and updates in Web3, Metaverse, Blockchain, AI, Cryptocurrencies, DeFi, NFTs, and Gaming. We provide comprehensive coverage through news, press releases, event updates, and research articles, keeping you informed about the rapidly evolving digital world.

  • About Web3Wire
  • Founder’s Note
  • Web3Wire NFTs – The Web3 Collective
  • .w3w TLD
  • $W3W Token
  • Web3Wire DAO
  • Event Partners
  • Community Partners
  • Our Media Network
  • Media Kit
  • RSS Feeds
  • Contact Us

Crypto Coins

  • Top 10 Coins
  • Top 50 Coins
  • Top 100 Coins
  • All Coins – Marketcap
  • Crypto Coins Heatmap

Crypto Exchanges

  • Top 10 Exchanges
  • Top 50 Exchanges
  • Top 100 Exchanges
  • All Crypto Exchanges

Crypto Stocks

  • Blockchain Stocks
  • NFT Stocks
  • Metaverse Stocks
  • Artificial Intelligence Stocks

Web3Wire Whitepaper | Tokenomics

Web3 Resources

  • Top Web3 and Crypto Youtube Channels
  • Latest Crypto News
  • Latest DeFi News
  • Latest Web3 News

Blockchain Resources

  • Blockchain and Web3 Resources
  • Decentralized Finance (DeFi) – Research Reports
  • All Crypto Whitepapers

Metaverse Resources

  • AR VR and Metaverse Resources
  • Metaverse Courses
Claim your space in Web3 with .w3w!

The Klyrox Protocol | The Algorithmic Monographs

Top 50 Web3 Blogs and Websites
Web3Wire Podcast on Spotify Web3Wire Podcast on Amazon Music 
Web3Wire - Web3 and Blockchain - News, Events and Press Releases | Product Hunt
Web3Wire on Google News

Media Portfolio: Block3Wire | Meta3Wire

  • Privacy Policy
  • Terms of Use
  • Disclaimer
  • Sitemap
  • For Search Engines
  • Crypto Sitemap
  • Exchanges Sitemap

© 2024 Web3Wire. We strongly recommend our readers to DYOR, before investing in any cryptocurrencies, blockchain projects, or ICOs, particularly those that guarantee profits.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Coins
    • Top 10 Cryptocurrencies
    • Top 50 Cryptocurrencies
    • Top 100 Cryptocurrencies
    • All Coins
  • Exchanges
    • Top 10 Cryptocurrency Exchanges
    • Top 50 Cryptocurrency Exchanges
    • Top 100 Cryptocurrency Exchanges
    • All Crypto Exchanges
  • Stocks
    • Blockchain Stocks
    • NFT Stocks
    • Metaverse Stocks
    • Artificial Intelligence Stocks

© 2024 Web3Wire. We strongly recommend our readers to DYOR, before investing in any cryptocurrencies, blockchain projects, or ICOs, particularly those that guarantee profits.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.